VNDA opened at $4.50 on Tuesday. Vanda Pharmaceuticals has a 12-month low of $3.87 and a 12-month high of $6.75. The firm has a market capitalization of $262.42 million, a P/E ratio of -14.06 and ...

WASHINGTON, March 31, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a New Drug Application (NDA) was submitted to the U.S. Food and Drug ...

Vanda Pharmaceuticals (VNDA) announced that a New Drug Application was submitted to the U.S. FDA requesting marketing approval of Bysanti for ...

Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. The firm had revenue of $53.19 million for the quarter, compared to analysts’ expectations of ...

Analysts' ratings for Vanda Pharmaceuticals (NASDAQ:VNDA) over the last quarter vary from bullish to bearish, as provided by 5 analysts. Summarizing their recent assessments, the table below ...

In a report released on April 1, David Risinger from Leerink Partners maintained a Buy rating on AnaptysBio (ANAB – Research Report). The ...

WASHINGTON - Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), currently valued at $273.5 million, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Bysanti ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...